We are leading efforts to address new challenges in translational medical research—but we can’t do it alone.
Through robust and meaningful collaboration, we bring our novel platforms directly to those who need it most, with coordinated care by notable experts in the field.
For more information or inquiries on collaborations and partnerships, please contact partnering@ovidrx.com.
Ovid currently has several ongoing corporate partnerships:
Takeda
In January 2017, Takeda and Ovid began an innovative clinical development and commercialization collaboration partnership to develop OV935/TAK-935 (soticlestat), a highly selective first-in-class CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control in rare developmental and epileptic encephalopathies (DEE). As part of this agreement, Ovid leads clinical development activities and commercialization in the United States, Europe, Canada and Israel. Takeda will lead commercialization in Japan, and has the option to lead in Asia and other selected geographies.
Lundbeck
In March 2015, Ovid entered into an exclusive worldwide license agreement for OV101 (gaboxadol) with Lundbeck, a global pharmaceutical company specialized in brain diseases. OV101, a highly selective GABAA receptor (GABAAR) agonist, has been tested in clinical trials and holds the potential to be the first oral medication to treat patients with Angelman syndrome and Fragile X syndrome. Under the terms of the agreement, Ovid obtained exclusive worldwide development and commercialization rights for OV101 and is responsible for all future development and commercialization for OV101.
